ASCO 2027

Discover remote patient monitoring in oncology at ASCO 2027

ASCO 2027 brings together the global oncology community to explore the latest advances in cancer care, research, and innovation. As new therapies continue to reshape oncology, healthcare teams face growing challenges: identifying which patients need attention first, managing treatment-related toxicities, and supporting patients safely between visits. These challenges are particularly relevant for patients receiving innovative treatments such as CAR T-cell therapies, bispecific antibodies, and other next-generation therapies, where close monitoring can help enable more outpatient and patient-centered care models.

How can remote patient monitoring support oncology care ?

• Support patients receiving oral therapies, CAR T-cell therapies, bispecific antibodies, and other complex treatments through continuous follow-up between visits.
• Detect symptoms and treatment-related toxicities early to enable timely intervention and help patients remain on treatment.
• Prioritize patients who need attention through intelligent alert management.
• Strengthen communication between patients and care teams throughout treatment.
• Generate real-world insights from patient-reported data to better understand treatment experiences and outcomes in routine clinical practice.
• Extend patient support capabilities through the Cureety Care Team

Cureety transforms patient-reported symptoms into a clear, prioritized view of who needs attention now. Care teams can identify toxicities earlier, intervene before they escalate, and keep patients supported throughout treatment. Through its Cureety Care Team in the United States, Cureety also helps organizations strengthen patient monitoring and engagement while generating valuable real-world evidence to inform clinical practice, research, and innovation.

‍Meet the Cureety team at ASCO 2027 to discover how remote patient monitoring, patient support services, and patient-reported data can help improve outcomes, support innovative therapies, and advance the future of oncology care.